Ginkgo Bioworks Holdings Inc (DNA)
0.4497
-0.01
(-2.66%)
USD |
NYSE |
Jun 14, 16:00
0.4518
0.00 (0.00%)
After-Hours: 20:00
Ginkgo Bioworks Holdings Free Cash Flow (Quarterly): -95.97M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -95.97M |
| December 31, 2023 | -61.28M |
| September 30, 2023 | -77.93M |
| June 30, 2023 | -87.07M |
| March 31, 2023 | -110.03M |
| December 31, 2022 | -130.18M |
| September 30, 2022 | -41.83M |
| Date | Value |
|---|---|
| June 30, 2022 | -108.98M |
| March 31, 2022 | -23.48M |
| December 31, 2021 | -170.66M |
| September 30, 2021 | -10.67M |
| June 30, 2021 | -58.94M |
| March 31, 2021 | -70.07M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-170.66M
Minimum
Dec 2021
-10.67M
Maximum
Sep 2021
-80.54M
Average
-77.93M
Median
Sep 2023
Free Cash Flow (Quarterly) Benchmarks
| Pacific Biosciences of California Inc | -79.56M |
| Teladoc Health Inc | -26.59M |
| Prime Medicine Inc | -70.03M |
| Inovio Pharmaceuticals Inc | -28.80M |
| Nektar Therapeutics | -48.04M |